|By PR Newswire||
|August 8, 2014 07:00 AM EDT||
SEATTLE, Aug. 8, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Wedbush PacGrow 2014 Life Sciences Management Access Conference in New York next week. The presentation is scheduled for Tuesday, August 12 at 12:45pm EDT.
The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at www.omeros.com.
About Omeros Corporation
Omeros is a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Derived from its proprietary PharmacoSurgery® platform, the Company's first drug product, Omidria™ (phenylephrine and ketorolac injection) 1%/0.3%, has been approved by the FDA for use during cataract surgery or intraocular lens replacement (ILR) to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. Omeros is completing preparations for an early fall 2014 U.S. product launch. Omidria is currently under review for marketing approval by the European Medicines Agency. Omeros' six clinical programs are focused on schizophrenia, Huntington's disease and cognitive impairment; addictive and compulsive disorders; complement-related diseases; and preventing problems associated with surgical procedures. Omeros also has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.
SOURCE Omeros Corporation
Dec. 9, 2016 11:30 PM EST Reads: 1,145
Dec. 9, 2016 10:45 PM EST Reads: 513
Dec. 9, 2016 10:30 PM EST Reads: 1,715
Dec. 9, 2016 10:00 PM EST Reads: 299
Dec. 9, 2016 09:45 PM EST Reads: 2,006
Dec. 9, 2016 09:30 PM EST Reads: 1,282
Dec. 9, 2016 08:00 PM EST Reads: 1,023
Dec. 9, 2016 07:45 PM EST Reads: 725
Dec. 9, 2016 06:45 PM EST Reads: 5,148
Dec. 9, 2016 06:15 PM EST Reads: 1,767
Dec. 9, 2016 05:30 PM EST Reads: 2,375
Dec. 9, 2016 05:15 PM EST Reads: 1,891
Dec. 9, 2016 05:15 PM EST Reads: 1,472
Dec. 9, 2016 05:15 PM EST Reads: 422
In his session at 19th Cloud Expo, Claude Remillard, Principal Program Manager in Developer Division at Microsoft, contrasted how his team used config as code and immutable patterns for continuous delivery of microservices and apps to the cloud. He showed how the immutable patterns helps developers do away with most of the complexity of config as code-enabling scenarios such as rollback, zero downtime upgrades with far greater simplicity. He also demoed building immutable pipelines in the cloud ...
Dec. 9, 2016 05:00 PM EST Reads: 2,079